文献速递放射性药物与辐射防护肿瘤 PET/CT

靶向巨噬细胞甘露糖受体CD206的氟-18标记甘露糖基化葡聚糖:小鼠验证研究

Macrophage mannose receptor CD206 targeting of fluoride-18 labeled mannosylated dextran: A validation study in mice.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-03-27

本研究在小鼠中验证了新型PET示踪剂Al[18F]F-NOTA-D10CM靶向巨噬细胞甘露糖受体CD206的能力。在CD206基因敲除小鼠中,肝脏和骨髓的示踪剂摄取显著低于野生型小鼠;在弗氏完全佐剂诱导的炎症模型中,静脉注射后炎症组织的摄取显著高于健康对照组织。示踪剂摄取与CD206阳性染色面积百分比正相关,提示该示踪剂在炎症显像方面有前景。

要点

  • 在CD206基因敲除小鼠中,肝脏和骨髓的Al[18F]F-NOTA-D10CM摄取显著低于野生型小鼠。
  • 静脉注射后,炎症踝关节和炎症足垫皮肤的示踪剂摄取显著高于健康小鼠对应组织。
  • 示踪剂在炎症组织的摄取与CD206阳性染色面积百分比正相关。

核心结论

  • 甘露糖基化葡聚糖衍生物Al[18F]F-NOTA-D10CM的摄取与CD206表达相关,该示踪剂在炎症显像方面似乎有前景。

研究设计与样本

  • 研究比较了静脉注射Al[18F]F-NOTA-D10CM在野生型(WT)与CD206基因敲除(KO)小鼠中的摄取。
  • C57BL/6N小鼠在左后腿注射弗氏完全佐剂(CFA),于诱导炎症后第5天和第14天研究静脉或皮内注射后的示踪剂摄取,并以健康C57BL/6N小鼠为对照。
  • 小鼠连续多日接受PET/CT,显像剂包括[18F]FDG、静脉注射Al[18F]F-NOTA-D10CM和皮内注射Al[18F]F-NOTA-D10CM,末次显像后行离体生物分布研究和炎症组织放射自显影。
  • 采用高效液相色谱分析血浆样本,并在炎症组织切片上通过放射自显影进行体外竞争置换实验以评估结合特异性,CD206表达以免疫组化染色评估。

主要发现

  • 与野生型小鼠相比,CD206基因敲除小鼠多个组织的Al[18F]F-NOTA-D10CM摄取显著降低,包括肝脏(SUV 8.21 ± 2.51 vs. 1.06 ± 0.16,P < 0.001)和骨髓(SUV 1.63 ± 0.37 vs. 0.22 ± 0.05,P < 0.0001)。
  • 静脉注射的Al[18F]F-NOTA-D10CM在炎症踝关节(SUV 0.48 ± 0.13 vs. 0.18 ± 0.05,P < 0.0001)和炎症足垫皮肤(SUV 0.41 ± 0.10 vs. 0.04 ± 0.01,P < 0.0001)的摄取显著高于健康小鼠对应组织。
  • 皮内注射的Al[18F]F-NOTA-D10CM显示CFA诱导的淋巴结活化与健康小鼠淋巴结之间存在差异。
  • 离体γ计数、放射自显影和免疫组化支持上述结果;在过量NOTA-D10CM的置换实验中,Al[18F]F-NOTA-D10CM的结合下降约80%,证实示踪剂结合具有特异性。
  • 静脉注射后60分钟,血浆放射性平均96.70%来自完整的Al[18F]F-NOTA-D10CM,表明体内稳定性良好;示踪剂在炎症组织的摄取与CD206阳性染色面积百分比正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Aluminum fluoride-18-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-conjugated mannosylated dextran derivative (Al[18F]F-NOTA-D10CM) is a new tracer for PET imaging. We report here on in vitro and in vivo validation of the tracer's ability to target the macrophage mannose receptor CD206. METHODS: First, the uptake of intravenously (i.v.) administered Al[18F]F-NOTA-D10CM was compared between wild-type (WT) and CD206-/- knockout (KO) mice. C57BL/6N mice were injected with complete Freund's adjuvant (CFA) in the left hind leg and the uptake of Al[18F]F-NOTA-D10CM after i.v. or intradermal (i.d.) injection was studied at 5 and 14 days after CFA induction of inflammation. Healthy C57BL/6N mice were studied as controls. Mice underwent PET/CT on consecutive days with [18F]FDG, i.v. Al[18F]F-NOTA-D10CM, and i.d. Al[18F]F-NOTA-D10CM. After the last imaging, Al[18F]F-NOTA-D10CM was i.v. injected for an ex vivo biodistribution study and autoradiography of inflamed tissues. Blood plasma samples were analyzed using high-performance liquid chromatography. To evaluate the specificity of Al[18F]F-NOTA-D10CM binding, an in vitro competitive displacement study was performed on inflamed tissue sections using autoradiography. CD206 expression was assessed by immunohistochemical staining. RESULTS: Compared with WT mice, the uptake of Al[18F]F-NOTA-D10CM was significantly lower in several CD206-/- KO mice tissues, including liver (SUV 8.21 ± 2.51 vs. 1.06 ± 0.16, P < 0.001) and bone marrow (SUV 1.63 ± 0.37 vs. 0.22 ± 0.05, P < 0.0001). The uptake of i.v. injected Al[18F]F-NOTA-D10CM was significantly higher in inflamed ankle joint (SUV 0.48 ± 0.13 vs. 0.18 ± 0.05, P < 0.0001) and inflamed foot pad skin (SUV 0.41 ± 0.10 vs. 0.04 ± 0.01, P < 0.0001) than in the corresponding tissues in healthy mice. The i.d.-injected Al[18F]F-NOTA-D10CM revealed differences between CFA-induced lymph node activation and lymph nodes in healthy mice. Ex vivo γ-counting, autoradiography, and immunohistochemistry supported the results, and a decrease of ~ 80% in the binding of Al[18F]F-NOTA-D10CM in the displacement study with excess NOTA-D10CM confirmed that tracer binding was specific. At 60 min after i.v. injection, an average 96.70% of plasma radioactivity was derived from intact Al[18F]F-NOTA-D10CM, indicating good in vivo stability. The uptake of Al[18F]F-NOTA-D10CM into inflamed tissues was positively associated with the area percentage of CD206-positive staining. CONCLUSION: The uptake of mannosylated dextran derivative Al[18F]F-NOTA-D10CM correlated with CD206 expression and the tracer appears promising for inflammation imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Andriana P, Fair-Mäkelä R, Liljenbäck H, et al. Macrophage mannose receptor CD206 targeting of fluoride-18 labeled mannosylated dextran: A validation study in mice. Eur J Nucl Med Mol Imaging. 2024. PMID: 38532026. doi:10.1007/s00259-024-06686-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。